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The aims of this study were to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetics of irinotecan
given with oral R115777 (tipifarnib), a farnesyl protein transferase inhibitor. Patients were treated with escalating doses of irinotecan
with interval-modulated dosing of R115777 (continuously or on days 1–14, and repeated every 21 days). In total, 35 patients were
entered onto the trial for a median duration of treatment of 43 days (range, 5–224 days). Neutropenia and thrombocytopenia were
the dose-limiting toxicities; other side effects were mostly mild. The MTD was established at R115777 300mg b.i.d. for 14
consecutive days with irinotecan 350mgm
 2 given every 3 weeks starting on day 1. Three patients had a partial response and 14 had
stable disease. In the continuous schedule, the area under the curves of irinotecan and its active metabolite SN-38 were 20.0%
(P¼0.004) and 38.0% (Po0.001) increased by R115777, respectively. Intermittent dosing of R115777 at a dose of 300mgb.i.d. for
14 days every 3 weeks is the recommended dose of R115777 in combination with the recommended single-agent irinotecan dose of
350mgm
 2.
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Over the past decade, the development of various new technologies
like genomics, high-throughput screening and combinatorial
chemistry has resulted in an explosion in the number of potential
targets for anticancer drugs (Anzick and Trent, 2002; McLeod,
2002). In addition, an improved understanding of signal transduc-
tion pathways has led to the identification of various G-proteins,
including Ras, which are critical intermediates of cell signalling
and cytoskeletal organisation (Adjei, 2001). Membrane localisation
of Ras proteins is catalysed by the enzyme farnesyl protein
transferase (FPT) and involves the addition of a farnesyl group to
conserved amino-acid residues at the carboxyl terminus (Kato et al,
1992). This process brings Ras into proximity to growth factor
receptors and coupling proteins allowing for activation of a
cascade of phosphorylation events through sequential activation of
the PI3 kinase/AKT pathway, which is critical for cell survival, and
the Raf/Mek/Erk kinase pathway, which has been implicated in cell
proliferation (Haluska et al, 2002).
As farnesylation of Ras is required for its activity, a series of FPT
inhibitors has been designed as potential anticancer agents to
abrogate its function (Rowinsky et al, 1999; Johnston, 2001).
Among numerous FPT inhibitors synthesised, two orally bioavai-
lable agents, sarasar (formerly SCH66336) (Ganguly et al, 2001)
and R115777 (tipifarnib, Zarnestra) (Venet et al, 2003), have
advanced to Phase II/III clinical development. The latter agent
is an orally bioavailable methyl-quinolone and belongs to the
class of nonpeptidomimetic FPT inhibitors with a broad spectrum
of preclinical antitumour activity (End et al, 2001; Kelland et al,
2001; Smith et al, 2002). Phase I clinical trials with single-agent
R115777 have been completed using both intermittent and
continuous dosing regimens (Hudes et al, 1999; Zujewski et al,
2000; Karp et al, 2001; Punt et al, 2001; Crul et al, 2002). The most
prominent dose-limiting side effects on regimens with twice-daily
(b.i.d.) dosing for up to 21 days relate to myelosuppression. With
continuous dosing (i.e., without rest periods), dose-limiting
myelosuppression and peripheral neuropathy were seen. In these
Phase I trials, evidence of activity was observed in a variety of
solid tumours, including colon (Zujewski et al, 2000) and non-
small-cell lung cancer (Crul et al, 2002). This observation provided
the rationale for initiation of a series of Phase II and Phase III
trials in breast (Johnston et al, 2002), colorectal (Cunningham
et al, 2002), glioma (Cloughesy et al, 2002), non-small-cell lung
(Adjei et al, 2002), pancreatic (Cohen et al, 2002; Macdonald
et al, 2002; Van Cutsem et al, 2002), prostate (Haas et al, 2002),
and small-cell lung cancer (Heymach et al, 2002). Activity has
been noted in breast cancer (Johnston et al, 2002), in acute
myelogenous leukaemia (Cortes et al, 2003) and myeloproliferative
disorders (Gotlib et al, 2002). The absence of activity in
gastrointestinal malignancies suggests that other directions for
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lthe development of this drug should be appraised. One of the
most promising of these is the evaluation of combination regimens
with classical cytotoxic agents with a distinctly different mode of
action (Moasser et al, 1998).
Against this background, we initiated a Phase I dose-escalation
trial to investigate the feasibility of the combination of R115777
given orally on a continuous or intermittent schedule and the
topoisomerase I inhibitor irinotecan, a prodrug of SN-38, given
intravenously once every 3 weeks. The objectives of this study were
(i) to assess the safety and toxicity profiles of this combination; (ii)
to determine the dose-limiting toxicities (DLTs), the maximum
tolerable doses (MTDs), and the recommended doses for further
trials; and (iii) to examine the effect of irinotecan on R115777
pharmacokinetics and vice versa.
PATIENTS AND METHODS
Eligibility criteria
Patients with a histologically or cytologically confirmed diagnosis
of a solid malignancy refractory to standard therapy or for whom
other treatment options were not available (e.g., pancreatic
cancer), were eligible for the present study. Additional eligibility
criteria included: (i) age at least 18 years; (ii) Eastern Cooperative
Oncology Group performance status p1; (iii) no previous
treatment with antineoplastic agents for at least 4 weeks (or 6
weeks in case of nitrosoureas or mitomycin C), and no more than
one prior chemotherapy regimen for advanced disease; (iv) no
prior treatment with topoisomerase I inhibitors; (v) no known
diagnosis of Gilbert’s syndrome or any other important contra-
indication for treatment with the normal prescribed dose of
irinotecan; (vi) no prior extensive (425%) radiotherapy of the
bone marrow region; and (vii) adequate hematopoietic (WBC
count, 43.5 10
9l
 1, and platelet count, 4100 10
9l
 1), renal
(serum creatinine concentration, p1.5  upper limit of institu-
tional normal (ULN)), and hepatic function (total serum bilirubin,
p1.5 ULN; aspartate aminotransferase and alanine aminotrans-
ferase, p2.5 ULN or p5 ULN in case of liver metastases). The
study protocol was approved by the Erasmus MC Review Board,
and all patients signed informed consent before study entry.
Drug administration
Irinotecan (Aventis, Antony Cedex, France) was administered once
every 3 weeks as a 90-min intravenous infusion after dilution of the
pharmaceutical preparation in 250ml of isotonic sodium chloride,
with the drug dose normalised to a patient’s body-surface area.
Premedication consisted of ondansetron (8mg intravenously) and
dexamethasone (10mg intravenously), both administered 30min
before irinotecan. Atropine (0.25mg subcutaneously) was admi-
nistered as a prophylaxis for irinotecan-induced acute cholinergic
syndrome in case the patient experienced this side effect in the
previous cycle. For delayed-type diarrhoea, patients received
loperamide (4mg orally), followed by a loperamide dose of 2mg
administered every 2h for up to 12h after the last liquid stool,
without exceeding a total of 48h of treatment. If diarrhoea
persisted for more than 24h, patients received a 7-day prophy-
lactic antibiotic course with ciprofloxacin. R115777 (Johnson &
Johnson Pharmaceutical Research and Development, Beerse,
Belgium) was provided as 100-, 200-, or 300-mg tablets, and
was administered orally at intervals of 12h with or immediately
after a meal.
Study design
The dose-escalation schemes for R115777 and irinotecan were
defined before the start of the study. R115777 was started at
300mg b.i.d. in the first patient, but based on emerging data from
other studies, for subsequent patients the starting dose was
reduced to 200mg b.i.d., with an escalating scheme for irinotecan,
starting at 200mgm
 2 and escalating steps of 50mgm
 2 up to the
registered single-agent dose, 350mgm
 2. Once the full dose of
irinotecan was reached, further escalation of R115777 would take
place in steps of 100mg b.i.d. Irinotecan was always given on day 1
of the first 3-week cycle and on day 1 of subsequent cycles. In the
continuous regimen, R115777 was administered on days 3–21 of
cycle 1, and then continuously thereafter, starting again on day 1 of
subsequent cycles. In the intermittent regimen, R115777 was
administered on days 3–14 of the first cycle, and then starting
again on day 1 of subsequent cycles, but without administration on
days 15–21.
Three patients were accrued at the starting dose level, and in the
absence of DLT, another three patients were entered at the next
dose level. For safety reasons, the next dose level was not opened
until at least three patients were assessable for toxicity in the first
cycle. In case only one patient developed DLT (see below), the dose
level was expanded with additional patients to a total of six. In case
DLT was reached in X2 of three or X2 of six patients, dose
escalation was ceased. The MTD (recommended dose) was defined
as one dose level below the level at which X2 of six patients
experienced DLT.
Toxicity and response evaluation
Toxicity was assessed by the National Cancer Institute Version 2.0
common toxicity criteria on a scale graded 0–4 (Available: http://
ctep.cancer.gov/reporting/ctc.html (accessed: February 27, 2004)).
DLT was defined as one or more of the following events: (i) grade 4
haematological toxicity lasting for more than 7 days and/or
associated with fever; (ii) any grade 3 or 4 nonhaematological
toxicity with the exception of untreated nausea, vomiting, and/or
alopecia; and/or (iii) an interruption of treatment for more than 3
weeks due to unresolved toxicity. Only events occurring during the
first two cycles of treatment were taken into consideration in
defining DLT. Tumours were assessed radiologically before
patients were enrolled on the study, and after every even-
numbered cycle. Response definitions were based on World
Health Organisation criteria (Available: http://www.who.int/home-
page/ (accessed: February 27, 2004)).
Sample collection and analysis
Plasma samples were collected for measurement of irinotecan, SN-
38, and R115777 concentrations. Irinotecan and SN-38 pharmaco-
kinetics were assessed on day 1 of cycle 1 and day 1 of cycle 2.
Plasma samples were collected for the measurement of R115777
concentrations on day 8 of cycle 1 (i.e. in the absence of irinotecan
co-administration), and again on day 1 of cycle 2 (i.e., in the
presence of irinotecan co-administration).
Blood samples for pharmacokinetic analysis were drawn from a
vein in the arm opposite to that used for irinotecan infusion, and
collected in 10-ml glass tubes containing lithium heparin as an
anticoagulant during the first and second cycles. Samples for
irinotecan pharmacokinetics were obtained before drug adminis-
tration; at 1h after start of infusion; at 5min before the end of
infusion; and at 30min, and approximately 1, 1.5, 2.5, 5.5, 9.5, 22.5,
and 46.5h after the end of infusion. Samples for R115777
pharmacokinetics were obtained immediately prior to administra-
tion; and at approximately 1, 2, 3, 5, 8, and 12 (before the next
dose)h after administration. Blood was immediately processed to
plasma by centrifugation for 5min at 3000 g (41C), and was then
stored at  801C until the time of analysis. Plasma samples were
assayed for total drug forms (i.e. lactone plus carboxylate) of
irinotecan and its metabolite SN-38, as well as for R115777 by
reversed-phase high-performance liquid chromatography as re-
ported in detail elsewhere (Sparreboom et al, 1998; Crul et al,
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l2002). Concentrations of the metabolites SN-38 glucuronide, APC
(7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbony-
loxycamptothecin), and R115777 glucuronide in plasma were not
measured because of limited sample supply that precluded the
required additional analysis on the same material.
Pharmacokinetic data analysis
Concentration–time data of irinotecan, SN-38, and R115777 were
analysed by standard noncompartmental methods using the
software package WinNonlin version 3.1 (Pharsight, Mountain
View, CA, USA). The peak concentration and the time to peak
concentration were the observed values. The AUC (AUC12h for
R115777; AUC48h for irinotecan and SN-38) was calculated
by trapezoidal summation. The terminal half-life was estimated
by linear regression of the log-transformed data. Parameter
predictions of the lactone and carboxylate forms of irinotecan
and SN-38 were calculated by previously developed models
(Xie et al, 2002). The considered parameters included clearance
and AUC. The latter parameter was simulated for irinotecan and
SN-38 from time 0 to 100h after the start of infusion in each
patient for a standard dose of 350mgm
 2. This data analysis
was performed using the software package NONMEM version VI
(SL Beal and LB Sheiner, San Francisco, CA, USA) with pooling of
data from patients administered R115777 continuously and
intermittently, which was carried out in order to increase the
power of detecting any significant association in view of the small
sample size.
Statistical considerations
For the noncompartmental pharmacokinetic parameters, an
analysis of variance was performed to generate appropriate
estimates allowing for the calculation of 90% confidence inter-
vals. A comparison between treatments (R115777 vs R115777þ
irinotecan, and irinotecan vs R115777þirinotecan) was made for
the parameters peak concentration and AUC. A general linear
model that included factors of patients, dose, and treatment was
used. The mean treatment ratio (combination therapy vs mono-
therapy) and the associated 90% confidence intervals were
calculated for log-transformed data using the mean square error
from the analysis of variance, expressed as a percentage. The
noncompartmental parameters from the continuous and inter-
mittent regimens of R115777 were analysed separately. Probability
values (two-sided) of less than 0.05 were regarded as statistically
significant. All statistical calculations were performed using JMP
version 3.2.6 (SAS Institute, Carey, NC, USA).
RESULTS
Patients and treatment
A total of 35 patients (19 men and 16 women) was enrolled onto
the study between April 1999 and July 2001 (Table 1). The majority
of patients had a diagnosis of colorectal cancer, and 26 had
previously failed on chemotherapy. Seven patients had only
received radiotherapy prior to the start of treatment, because
other treatment options were considered not available per the
standard Dutch treatment guidelines. Patients with metastatic
colorectal cancer were treated with relatively low doses of
irinotecan in the early phases of this study, because at that time
the use of irinotecan was not yet considered the standard
treatment option for this indication. The first four cohorts of
patients were treated with continuous R115777 at 200mg b.i.d. In
all, 17 subjects were treated at this dose in combination with
irinotecan at 200mgm
 2 (four patients, including the first patient
who received R115777 at 300mg b.i.d.), 250mgm
 2 (n¼4),
300mgm
 2 (n¼3) or 350mgm
 2 (n¼6) in 21-day cycles. The
observation of the occurrence of cumulative fatigue as well as a
pharmacokinetic interaction between R115777 and SN-38 (see
below) resulted in the decision to change the administration of
R115777 from a continuous to an intermittent schedule. A total of
18 additional patients were treated at R115777 doses of 200mg
b.i.d., 300mg b.i.d. or 400mg b.i.d. (n¼6 in each group) given
intermittently (days 1–14 every 21 days) in combination with
irinotecan at 350mgm
 2. The median number of cycles was 2
(range, 1–10 cycles), and the median duration of treatment was 43
days (range, 5–224 days). The median daily drug dose adminis-
tered was close to the planned dose for both drugs in each
treatment group.
Toxicity profiles
During the entire course of treatment, all patients experienced
one or more adverse events, and these were of grade 3 or 4
severity in 22 patients. The majority of grade 3 or 4 adverse events
had already occurred in cycles 1 and 2 (Table 2). Overall, 16
patients (45.7%) had drug-related, grade 3 or 4 adverse events. The
most frequently reported nonhaematological drug-related events
were diarrhoea (n¼5), fatigue (n¼4), vomiting (n¼3), and
nausea (n¼2). The most frequently reported grade 3 or 4
haematological events leading to treatment intervention were
neutropenia/febrile neutropenia (n¼5), and thrombocytopenia
(n¼2). Three patients had systemic infections as a result of
neutropenia, and 13 were withdrawn due to severe adverse events,
mostly due to vomiting, nausea, and diarrhoea (n¼3 each). One
patient died during the study of a bowel perforation, which was not
considered related to the study medication. For all cohorts, DLTs
were observed in a total of seven patients in cycles 1 or 2. The main
DLTs were related to neutropenia (n¼4). In the continuous
dosing regimen (200mg b.i.d. R115777), DLT was recorded for one
of eight patients administered o300mgm
 2 irinotecan (febrile
neutropenia), one of three patients given 300mgm
 2 irinotecan
(fatigue), and one of six patients in the cohort given 350mgm
 2
irinotecan (febrile neutropenia and thrombocytopenia). The
MTD was not formally established with the continuous R115777
regimen, although irinotecan was administered at the full-
Table 1 Patient demographics
Characteristic Value
Number entered 35
Male 19
Female 16
Age (years) 52 (34–75)
a
Weight (kg) 74 (39–114)
a
Ethnicity
Caucasian 34
Asian 1
Primary site
Cervical 1
Colorectal 17
Oesophageal 4
Pancreatic 4
Papilla of vater 1
Small intestinal 1
Unknown 7
Previous therapy
None 2
Chemotherapy 26
Radiotherapy 7
aMedian with range in parentheses.
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lrecommended dose. However, in later courses seven of 17
patients developed severe fatigue necessitating treatment disconti-
nuation in one of them. The long-term treatment with this
schedule will be difficult and is not recommended for further
study. In the intermittent regimen (all given irinotecan at
350mgm
 2), DLT was recorded in one of six patients at 200mg
b.i.d. R115777 (neutropenia with infection), one of six patients
at 300mg b.i.d. R115777 (grade 3 aspartate aminotransferase)
and two of six patients at 400mg b.i.d. R115777 (febrile
neutropenia and thrombocytopenia in one, and nausea, fatigue
and vomiting in the other). The MTD was established at 300mg
b.i.d. R115777 administered for 14 days in 21-day cycles with
irinotecan at 350mgm
 2 given every 3 weeks. At this dose
level, the combination therapy was tolerated remarkably well
(Table 3).
Antitumour activity
Of 35 patients, 30 were assessable for response as per the
protocol guidelines, but the following was analysed on an intention
to treat basis. Three (8.6%) patients achieved a partial response
to therapy, one each with papilla of vater adenocarcinoma,
unknown primary adenocarcinoma, and moderately differentiated
squamous cell carcinoma of the cervix. In addition, 14 patients
(40%) had stable disease, and 13 (37%) patients had progression
of disease.
Irinotecan disposition
The plasma concentration–time profiles of irinotecan and SN-38
were similar for all patients studied, with representative examples
shown in Figure 1. Over the various dose ranges studied, the AUC
and the peak plasma concentrations of irinotecan increased in
proportion with dose (P¼0.43), albeit with substantial interpatient
variability (i.e. greater than two-fold). In the absence of R115777,
irinotecan and SN-38 pharmacokinetics, calculated by noncom-
partmental analysis, were very similar to previous single-agent
data (Mathijssen et al, 2001). In the group of patients treated in
combination with R115777 administered on a continuous sche-
dule, the dose-normalised irinotecan AUC48h was 20.0% increased
as compared to the control (P¼0.004) (Table 4). Likewise, the
AUC48h of SN-38 was 38.0% increased (Po0.001) in the presence
of R115777. After changing the R115777 administration to an
intermittent schedule, the pharmacokinetic interaction was sub-
stantially less as a 12% (P¼0.074) and 16.0% (P¼0.022) increase
in the AUC48h of irinotecan and SN-38, respectively, was observed
(Table 4). Differences in irinotecan pharmacokinetics were also
observed for the lactone and carboxylate forms, as estimated using
a previously defined population model (Table 5). The observed
plasma concentration–time profiles of irinotecan and SN-38 were
Table 2 Incidence of grade 3 or 4 drug-related toxicity in cycles 1 and 2
a
Continuous Intermittent
Dose level 1 2 3 1 2 3 Total (%)
R115777 dose (mg) 200 200 200 200 300 400
Irinotecan dose (mgm
 2) o300 300 350 350 350 350
No. of patients studied 8 3 6 6 6 6 35
No. with grade 3 or 4 AE 1
b 23
b 12
b 4 13 (37.1)
Haematological toxicity
Anaemia — — — — — 1 1 (2.9)
Febrile neutropenia 1 — 1
b — — 1 3 (8.6)
Leukocytopenia 1 — — — — — 1 (2.9)
Neutropenia — — — — — 1 1 (2.9)
Thrombocytopenia — — 1 — — — 1 (2.9)
Nonhaematological toxicity
Bacterial infection — — — 1 — 1 2 (5.7)
Diarrhoea — — 1
b 1—
b 1 3 (8.6)
Fatigue — 1 —
b ——
b 1 2 (5.7)
Hypotension — — 1 — — — 1 (2.9)
Nausea — — — — — 1 1 (2.9)
Rash — 1 — — — — 1 (2.9)
Sepsis 1 — — — — — 1 (2.9)
ALT increase — — — — 1
b — 1 (2.9)
Vomiting — — — — 1 1 2 (5.7)
aThe classification of drug-related includes a possible, probable, or very likely relationship to R115777 and/or irinotecan treatment. Numbers indicate number of patients, unless
stated otherwise.
bAt least one (additional) patient experienced grade 3 or 4 drug-related side effect in a cycle beyond 1 and 2. AE¼adverse effect.
Table 3 Drug-related nonhaematological toxicity at MTD
a
Cycle 1 Cycle 2 Cycle X3
Gr 1/2 Gr 3/4 Gr 1/2 Gr 3/4 Gr 1/2 Gr 3/4
Nausea 5 — 4 — 4 —
Vomiting 5 — 3 1
b 3—
Diarrhoea 5 — 6 — 3 1
Abdominal pain 2 — — — 1 —
Dizziness 2 — — — 1 —
Insomnia/somnolence 2 — 1 — — —
Malaise 1 — — — 1 —
Fatigue 3 — 4 — 1 1
b
Rash 1 — 1 — — —
Weight decrease — — 1 — 2 —
Alopecia 2 — 1 — 2 —
aThe classification of drug-related includes a possible, probable, or very likely
relationship to R115777 and/or irinotecan treatment. Numbers indicate number of
patients out of a total of 6 (5 for cycle X3) treated with R115777 at 300mg b.i.d.
administered for 14 days in 21-day cycles with irinotecan at 350mgm
 2 given every 3
weeks.
bRepresents the same patient. Gr¼grade.
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lwell predicted by this model, as indicated by goodness-of-fit plots
(Figure 2).
R115777 pharmacokinetics
The pharmacokinetic behaviour of R115777 was also very similar
to previous single-agent data (Table 6) (Zujewski et al, 2000; Crul
et al, 2002). The peak plasma concentrations of R115777 were
typically observed at 2h after oral administration either with or
without co-administration of irinotecan. On average, the increase
in AUC (1.0%; P¼0.97) and decrease in the peak concentration
(7.0%; P¼0.75) of R115777 in the combination therapy were not
significant relative to those following continuous monotherapy.
The substantial variability in both of these parameters for R115777
contributed to wide 90% confidence intervals (combination
therapy vs R115777 alone). The slight increases in the AUC
(9.0%; P¼0.35) and peak concentration (6.0%; P¼0.55) of
R115777 in the intermittent regimens following administration of
irinotecan were also not statistically significant. This suggests that
irinotecan does not substantially influence the systemic disposition
of R115777.
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Figure 1 Plasma concentration vs time profiles of irinotecan (circles) and
SN-38 (squares) in two representative patients treated with irinotecan at a
dose of 350mgm
 2 as a 90-min infusion either given alone (closed
symbols) or in combination with a 300-mg b.i.d. oral dose of R115777
(open symbols) given on a continuous (A) or intermittent (B) regimen.
Table 4 Noncompartmental analysis of irinotecan pharmacokinetics
Parameter ( ) R115777 (+) R115777 P-value Ratio
a
Continuous
b
Irinotecan
Cmax (ngml
 1) 38897801 39927938 0.72 102 (92–113)
AUC48h (nghml
 1) 2089173793 2544277011 0.004 120 (110–131)
t1/2 (h) 9.2572.06 9.6571.15 n/a n/a
SN-38
Cmax (ngml
 1) 63.4737.4 70.2749.6 0.37 110 (92–132)
AUC48h (nghml
 1) 3977195 5697328 o0.001 138 (123–156)
t1/2 (h) 13.474.44 21.479.76 n/a n/a
Intermittent
c
Irinotecan
Cmax (ngml
 1) 36207632 37107620 0.54 103 (96–110)
AUC48h (nghml
 1) 2027076020 2258076330 0.074 112 (101–124)
t1/2 (h) 10.171.00 10.071.30 n/a n/a
SN-38
Cmax (ngml
 1) 41.5720.1 42.9719.7 0.55 104 (93–116)
AUC48h (nghml
 1) 3267134 3757146 0.022 116 (105–128)
t1/2 (h) 18.1713.1 19.3710.3 n/a n/a
Cmax¼peak plasma concentration; AUC48h¼area under the plasma concentration–
time curve up to 48h after irinotecan administration; t1/2¼half-life of the terminal
disposition phase; P-value¼probability value from a two-sided, paired Student’s t-
test; n/a¼not applicable.
aBased on least-squares means calculated as the ratio of test
(irinotecan with R115777) to reference (irinotecan alone), with 90% confidence limits
(in log scale and expressed as a percent of single-agent irinotecan) in parentheses.
bData were obtained from 11–13 patients receiving irinotecan (dose, 200–
350mgm
 2) in the absence (cycle 1) or presence (cycle 2) of oral R115777 (dose,
200mg b.i.d.) and analysed using noncompartmental analysis. Data are expressed as
mean values7s.d., with Cmax and AUC representing dose-adjusted values (to
350mgm
 2).
cData were obtained from 13 patients receiving irinotecan (dose,
350mgm
 2) in the absence (cycle 1) or presence (cycle 2) of oral R115777 (dose,
200–400mg b.i.d.), and analysed using noncompartmental analysis. Data are
expressed as mean values7s.d.
Table 5 Compartmental analysis of irinotecan pharmacokinetics
a
Parameter ( ) R115777 (+) R115777 Mean diff
b P-value
Irinotecan
AUClac (nghml
 1) 53807727 56507666  2697101 0.067
AUCcar (nghml
 1) 1240073710 1430074840  19507641 0.0027
CLlac (lh
 1) 80.6716.6 73.1716.6 7.4472.35 0.998
CLcar (lh
 1) 11.671.74 11.071.71 0.5470.22 0.989
SN-38
AUClac (nghml
 1) 3687154 4287273  59.7734.7 0.049
AUCcar (nghml
 1) 108745.8 135757.5  26.7710.1 0.0071
REClac (%) 6.9173.05 7.4874.45  0.5770.50 0.135
RECtotal (%) 2.7271.02 2.8271.22  0.0970.13 0.227
AUC¼simulated area under the plasma concentration–time curve up to 100h after
drug administration; lac¼lactone form; car¼carboxylate form; CL¼clearance;
REC¼relative extent of conversion (AUCSN-38/AUCirinotecan 100%); P-value¼-
probability value from a two-sided, paired Student’s t-test.
aData were obtained from
26 patients receiving irinotecan (dose, 200–350mgm
 2) in the absence (cycle 1)
and presence (cycle 2) of oral R115777 (dose, 200–400mg b.i.d.), and analysed using
a population pharmacokinetic model. Data are expressed as dose-normalised (to
350mgm
 2) mean values7s.d.
bMean difference (cycle 2–cycle 1)7s.d.
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lDISCUSSION
This phase I study was performed to assess the safety and
determine the MTD of a combination of twice-daily oral dosing of
the FPT inhibitor R115777 and irinotecan administered in a once
every 3 weeks schedule. Overall, the study demonstrates that this
combination is fairly well tolerated, and that no unexpected
toxicities were observed beyond those known with the respective
single-agent regimens of both drugs. It was observed, however,
that seven of 17 patients developed cumulative fatigue in the group
of patients treated with continuous dosing of R115777. During the
course of the trial, this observation combined with the notion of a
pharmacokinetic interaction between R115777 and irinotecan
prompted a change of R115777 dosage schedule from continuous
to intermittent, consisting of drug dosing on 14 consecutive days
every 21 days. In this intermittent regimen, DLT was observed at
the standard dose of irinotecan of 350mgm
 2 and R115777 at a
dose of 400mg b.i.d., and consisted of febrile neutropenia in
combination with thrombocytopenia or nausea, vomiting and
fatigue. Other side effects were mostly mild and included rash and
diarrhoea. The MTD was established at 300mg b.i.d. of R115777
administered orally for 14 consecutive days in combination with
irinotecan given at 350mgm
 2 every 3 weeks.
The pharmacokinetic data generated in this trial for irinotecan
given alone were very similar to those described previously
(Mathijssen et al, 2001). In the presence of R115777, however, the
systemic exposure to total drug levels of irinotecan and its
metabolite SN-38 was substantially increased, especially following
continuous administration of R115777. Data from pharmacoki-
netic modelling further suggest that this interaction is most closely
linked to effects on the carboxylate form of irinotecan. It was
clearly beyond the scope of this investigation to unravel the
mechanism behind the observed interaction. However, a possible
explanation would be the fact that R115777 is known to inhibit
CYP3A4 activity in human hepatic microsomal preparations, albeit
at in vitro concentrations that are five-fold higher than the peak
concentrations observed in the present study (Bohets, 1998).
Previous investigations have shown that inhibition of CYP3A4 in
patients on irinotecan treatment leads to shunting of parent drug
to esterase-mediated hydrolysis to form SN-38 (Kehrer et al, 2002).
The notion that the primary CYP3A4-mediated irinotecan
metabolite APC is formed out of the carboxylate form of irinotecan
(Xie et al, 2002), the pharmacokinetics of which are affected most,
lends further support to a prominent role of CYP3A4 in the
metabolism of irinotecan. However, evidence against inhibition of
CYP3A4 activity by R115777 was observed in a previous
interaction study with another CYP3A4 substrate, docetaxel;
single-dose administration of R115777 (200 or 300mg) was shown
to have little effect on the systemic exposure to docetaxel. In a
subset of subjects, the plasma AUC of docetaxel was relatively
unchanged by continuous R115777 (200mg b.i.d.) administration
(unpublished data, Johnson & Johnson Pharmaceutical Research
and Development).
Alternatively, as both irinotecan and R115777 are known to be
extensively metabolised by UGT1A (Hanioka et al, 2001; Garner
et al, 2002), it is also possible that competitive inhibition of this
class of enzymes by R115777 results in impaired glucuronidation
of SN-38, and hence leads to an increase in circulating levels of
unconjugated SN-38 in plasma. However, recent preclinical studies
suggest that UGT1A1, UGT1A7, and UGT1A9 are the major
isozymes involved in SN-38 glucuronidation, with a minor role for
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Figure 2 Logarithm of the individual predicted concentrations (LogIPRED) vs the observed concentrations (LogDV) of irinotecan (CPT-11; left panel)
and SN-38 (right panel). All concentrations are in units of ngml
 1.
Table 6 Noncompartmental analysis of R115777 pharmacokinetics
Parameter ( ) Irinotecan (+) Irinotecan P-value Ratio
a
Continuous
b
tmax (h) 2.0 2.1 n/a n/a
Cmax (ngml
 1) 8407551 7357377 0.75 93 (63–137)
AUC12h (nghml
 1) 324071590 300071540 0.97 101 (68–149)
Intermittent
c
tmax (h) 2.0 2.0 n/a n/a
Cmax (ngml
 1) 6107248 6637296 0.55 106 (89–126)
AUC12h (nghml
 1) 282071070 317071550 0.35 109 (93–127)
tmax¼time to peak concentration; Cmax¼peak plasma concentration;
AUC12h¼area under the plasma concentration–time curve up to 12h after drug
administration; P-value¼probability value from a two-sided, paired Student’s t-test;
n/a¼not applicable.
aBased on least-squares means calculated as the ratio of test
(R115777 with irinotecan) to reference (R115777 alone), with 90% confidence limits
(in log scale and expressed as a percent of single-agent R115777) in parentheses.
bData were obtained from 11–13 patients receiving oral R115777 (dose, 200mg
b.i.d.) in the absence (cycle 2) or presence (cycle 1) of irinotecan (dose, 200–
350mgm
 2), and analysed using noncompartmental analysis. Data are expressed as
mean values7s.d., except tmax (median value).
cData were obtained from 12–13
patients receiving oral R115777 (dose, 200–400mg b.i.d.) in the absence (cycle 2) or
presence (cycle 1) of irinotecan (dose, 350mgm
 2), and analysed using
noncompartmental analysis. Data are expressed as dose-normalised (to 200mg)
mean values7s.d., except tmax (median value).
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lUGT1A6, UGT1A8, and UGT1A10 (Gagne et al, 2002), whereas
UGT1A4 is the prominent isozyme producing the N-glucuronide of
R115777, with a minor role for UGT1A3 (Mannens et al, 2002).
This makes an interaction between R115777 glucuronidation and
SN-38 elimination at this level less likely.
Irinotecan undergoes complex and extensive biotransformation
and elimination processes (Mathijssen et al, 2001). Besides
oxidation and glucuronidation, irinotecan and SN-38 may be
secreted by ABCB1 (P-glycoprotein), ABCC2 (MRP2 or cMOAT),
and ABCG2 (BCRP or MXR). At present, it is unknown whether
R115777 inhibits ABCC2 and/or ABCG2, or whether R115777 is a
substrate for one or more of these transporters. There is some
preliminary data for ABCB1 indicating that R115777 is not likely to
be a substrate, and at physiologically relevant concentrations,
R115777 does not significantly inhibit P-glycoprotein (unpub-
lished data, Johnson & Johnson Pharmaceutical Research and
Development). Therefore, the exact mechanism underlying the
interaction between R115777 and irinotecan remains unclear and
requires further investigation. However, the effect is apparently
reversible, since a significant increase in irinotecan and SN-38
concentrations was observed following continuous R115777
administration but not following intermittent dosing. Most
importantly, the clinical relevance of the observed interaction
remains limited, since both irinotecan and R115777 could be safely
given in combination at their full recommended single-agent doses.
The pharmacokinetics of R115777 given in the absence of
irinotecan was also consistent with previous findings from patients
on similar regimens (Zujewski et al, 2000; Crul et al, 2002). Recent
data from a mass-balance study indicate that R115777 is very
extensively metabolised to multiple products in addition to its
major metabolite R115777-glucuronide (Garner et al, 2002). The
major metabolic routes are a de-methylation on the quinolinone
core as well as successive oxidation reactions of the C6-amino
moiety resulting in loss of the methyl-imidazole moiety, which is
most likely mediated by CYP3A isoforms. In an attempt to gain
insight into the causes of the substantial interindividual variability
in drug handling, an exploratory analysis of the associations
between R115777 pharmacokinetics and genetic variants of genes
with a putative role in its absorption and disposition character-
istics is currently being performed.
In conclusion, intermittent dosing of R115777 at a dose of
300mg b.i.d. for 14 consecutive days is feasible in combination
with the standard dosage of irinotecan at 350mgm
 2 given once
every 3 weeks.
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